Open Access<p>Combination Chemotherapy of Lung Cancer – Co-Delivery of Docetaxel Prodrug and Cisplatin Using Aptamer-Decorated Lipid–Polymer Hybrid Nanoparticles</p>
Author(s) -
Runze Wu,
Zhiqiang Zhang,
Baohua Wang,
Ge Chen,
Yao-Zhong Zhang,
Haowen Deng,
Zhonglin Tang,
Junjie Mao,
Lei Wang
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s246574
Subject(s) - docetaxel , cisplatin , prodrug , aptamer , pharmacology , in vivo , cytotoxicity , chemistry , lung cancer , cancer cell , chemotherapy , cancer research , cancer , in vitro , medicine , biochemistry , oncology , microbiology and biotechnology , biology
Lung cancer is the leading cause of cancer mortality worldwide. Drug resistance is the major barrier for the treatment of non-small cell lung cancer (NSCLC). The aim of this research is to develop an aptamer-decorated hybrid nanoparticle for the co-delivery of docetaxel prodrug (DTXp) and cisplatin (DDP) and to treat lung cancer.